New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has notified the retail prices of 39 medicines, making it mandatory for pharmaceutical companies to market these formulations at the newly approved rates.
The decision has been issued under the provisions of the Drugs (Prices Control) Order (DPCO), 2013, with the objective of ensuring that essential medicines remain available to patients at regulated and affordable prices.
According to the notification, the newly priced medicines cover a broad range of therapeutic categories. These include treatments for diabetes, blood pressure, liver disorders, antibiotics, eye-related conditions, Vitamin D3 supplements, cancer therapies, and medicines used in the management of HIV, among others.
The NPPA stated that all manufacturers introducing these formulations into the market will be required to adhere to the retail prices approved by the authority. Companies have also been directed to ensure that the revised prices are reflected in accordance with existing pricing regulations.
The authority regularly reviews the prices of medicines launched in the market to maintain transparency and prevent unreasonable pricing. Under the DPCO framework, pharmaceutical firms are required to seek approval of retail prices for certain new formulations before they are sold commercially.
Health sector experts believe that the move will help improve affordability for patients requiring long-term treatment, particularly those suffering from chronic illnesses such as diabetes and hypertension. Price regulation is also expected to reduce variation in the cost of medicines across different brands.
The NPPA functions under the Department of Pharmaceuticals and is responsible for monitoring the prices of medicines, enforcing price control mechanisms and ensuring compliance with government regulations.
Officials said the latest notification is part of the government’s continuing efforts to strike a balance between making medicines affordable for consumers and ensuring a stable environment for pharmaceutical manufacturers.
The revised retail prices will come into effect as specified in the official notification, and companies failing to comply with the prescribed rates could face action under the provisions of the Drugs (Prices Control) Order, 2013.
